Checkpoint Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 23
- Market Cap
- -
- Website
- http://www.checkpointtx.com
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
Phase 3
Terminated
- Conditions
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Interventions
- Dietary Supplement: Folic acid 350-1000 μgDietary Supplement: Vitamin B12 1000 μg
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Checkpoint Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04786964
- Locations
- 🇹ðŸ‡
Research Site, Chiang Mai, Thailand
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Phase 1
Active, not recruiting
- Conditions
- Malignant Mesothelioma, AdvancedMelanomaCutaneous Squamous Cell CarcinomaNon Hodgkin LymphomaLung NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Small CellHead and Neck CancerEndometrial CancerMerkel Cell Carcinoma
- Interventions
- Drug: CK-301 (cosibelimab)
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Checkpoint Therapeutics, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03212404
- Locations
- 🇺🇦
Research Site, Sumy, Ukraine
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Lung DiseasesCarcinoma, Non-Small-Cell LungLung NeoplasmsAdenocarcinoma
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Checkpoint Therapeutics, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT02926768
- Locations
- 🇹ðŸ‡
Research Site, Bangkok Noi District, Bangkok, Thailand
🇹ðŸ‡Research Site, Pathumwan, Bangkok, Thailand
🇹ðŸ‡Research Site, Khon Kaen, Thailand
© Copyright 2025. All Rights Reserved by MedPath